CNTA Jun 2024 7.500 put
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 2.5000 |
| Strike | 7.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksDown -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024Location: NY, NYFireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare ConferenceDate: June 11
Globe NewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101
